Predictive genetic testing (PGT) comprises analysis of genes, the whole genome, or exomes to predict the risk of a wide range of disorders. It can have long-term implications in preventive healthcare practices, including delayed onset of disease, treatment management, pharmacogenomics, and general wellness. One outcome of the COVID-19 pandemic has been increased focus on preventive healthcare practices from a consumer wellness perspective, and PGT technology complements this desire for preventive and personalized healthcare and wellness monitoring tools. As such, PGT platforms are likely to experience increased global uptake in the next 5 years.
Industry convergence is rising among consumer genetic testing, diagnostic, and pharma companies due to increasing focus on holistic and hyper-personalized healthcare practices. Also, collaboration with pharma and diagnostic companies is on the rise as companies look to deliver targeted therapeutic innovations. This is likely to advance new product development for precision medicine applications in the future. This Frost Radar provides insights across leading clinical and predictive consumer genetics companies that use microarrays, whole genome sequencing (WGS), whole exome sequencing (WES), and targeted sequencing platforms. Key applications areas for such technologies include pharmacogenomic, prenatal, reproductive health, newborn, hereditary cancer risks, rare disease risk, and health and wellness assessment. Emerging application areas for PGT technologies include population-scale genomics for drafting nationwide preventive healthcare guidelines.
Next-generation sequencing (NGS) technologies have high growth potential to fuel new advances in the global PGT landscape. Technology advances in artificial intelligence (AI) and machine learning (ML) platforms will help users derive actionable healthcare insights from a large pool of genomic data. Integration of these advanced technologies is also likely to fuel progress tied to improving insights across population-scale genomics studies. Leading companies in the PGT space are collaborating with pharma companies to develop precision diagnostic and therapeutic innovations. Some companies are also looking to leverage the large-scale genomic data for population genomic analyses.
Frost & Sullivan analyzes numerous companies in an industry. Those selected for further analysis based on their leadership or other distinctions are benchmarked across 10 Growth and Innovation criteria to reveal their position on the Frost Radar. The publication presents competitive profiles of each company on the Frost Radar considering their strengths and the opportunities that best fit those strengths.
Strategic Imperative
Growth Environment
Growth Environment (continued)
Frost Radar™: Predictive Genetic Testing Technologies
Frost Radar™
BGI Genomics
Myriad Genetics
Natera, Inc.
Invitae
Veritas Genetics
Ancestry
Color Health
GeneDx
23andMe
Prenetics
Strategic Insights
Significance of Being on the Frost Radar™
Frost Radar™ Empowers the CEO’s Growth Team
Frost Radar™ Empowers Investors
Frost Radar™ Empowers Customers
Frost Radar™ Empowers the Board of Directors
Frost Radar™: Benchmarking Future Growth Potential
Frost Radar™: Benchmarking Future Growth Potential
Legal Disclaimer
Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform
Growth Index
Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.
- Market Share (previous 3 years)
This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years. - Revenue Growth (previous 3 years)
This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™. - Growth Pipeline
This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities. - Vision and Strategy
This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision? - Sales and Marketing
This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.
Innovation Index
Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.
- INNOVATION SCALABILITY
This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals. - RESEARCH AND DEVELOPMENT
This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline. - PRODUCT PORTFOLIO
This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue. - MEGATRENDS LEVERAGE
This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline. - CUSTOMER ALIGNMENT
This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.
Significance of Being on the Frost Radar™
Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.
- GROWTH POTENTIAL
Your organization has significant future growth potential, which makes it a Company to Action. - BEST PRACTICES
Your organization is well positioned to shape Growth Pipeline™ best practices in your industry. - COMPETITIVE INTENSITY
Your organization is one of the key drivers of competitive intensity in the growth environment. - CUSTOMER VALUE
Your organization has demonstrated the ability to significantly enhance its customer value proposition. - PARTNER POTENTIAL
Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Frost Radar |
|---|---|
| Author | Vandana Iyer |
| Industries | Healthcare |
| No Index | No |
| Is Prebook | No |
| Keyword 1 | Predictive Testing Innovations |
| Keyword 2 | Genetic Testing Industry Trends |
| Keyword 3 | Genetic Diagnostics Research Reports |
| Podcast | No |
| WIP Number | DACC-01-00-00-00 |
Frost Radar™: Predictive Genetic Testing Technologies, 2023
A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
16-Oct-2023
Global
Frost Radar
